{"id":"NCT00312572","sponsor":"Purdue Pharma LP","briefTitle":"Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain","officialTitle":"A Randomized, Double-Blind Study Evaluating the Dose Conversion From Vicodin® to Buprenorphine Transdermal System (BTDS) in Subjects With Osteoarthritis (OA) Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-06","primaryCompletion":"2004-07","completion":"2004-07","firstPosted":"2006-04-10","resultsPosted":"2010-09-23","lastUpdate":"2012-09-03"},"enrollment":204,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis"],"interventions":[{"type":"DRUG","name":"Buprenorphine transdermal patch","otherNames":["Butrans™"]}],"arms":[{"label":"BTDS10/20","type":"EXPERIMENTAL"},{"label":"BTDS 20","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to evaluate the safety and efficacy of dose conversion from hydrocodone/ acetaminophen (Vicodin®) to the buprenorphine transdermal system (Butrans™) in subjects with osteoarthritis pain of the hip or knee. The double-blind treatment intervention duration is 2 weeks during which time supplemental analgesic medication will be allowed.","primaryOutcome":{"measure":"The Percentage of Subjects Who Completed the 14-day Double-blind Phase.","timeFrame":"14 days","effectByArm":[{"arm":"Double-blind BTDS 10/20","deltaMin":88,"sd":null},{"arm":"Double-blind BTDS 20","deltaMin":83,"sd":null},{"arm":"Combined Total","deltaMin":85,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":2},"locations":{"siteCount":36,"countries":["United States"]},"refs":{"pmids":["22409388"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":101},"commonTop":["Application site pruritus","Headache","Nausea","Somnolence","Vomiting NOS"]}}